CagriSema is the most significant metabolic peptide combination to enter clinical research since tirzepatide, and its Phase 3 data has fundamentally changed how researchers think about weight management.

CagriSema is the most significant metabolic peptide combination to enter clinical research since tirzepatide, and its Phase 3 data has fundamentally changed how researchers think about weight management. Developed by Novo Nordisk as a fixed-dose combination of cagrilintide (a long-acting amylin analogue) and semaglutide (a GLP-1 receptor agonist), CagriSema represents the first serious attempt to combine two distinct satiety pathways into a single weekly injection for body weight reduction.

The clinical program behind CagriSema — spanning multiple Phase 3 trials across thousands of participants — has produced weight loss data that places it among the most effective investigational compounds ever studied for obesity. For researchers studying metabolic peptides, understanding how CagriSema works, what the trial data actually shows, and how it compares to existing GLP-1 and multi-agonist approaches is now essential context. This guide covers the mechanism, the published clinical evidence, and what the research landscape looks like in 2026.

What Is CagriSema and How Does It Work?

CagriSema is a co-formulated combination of two peptides: cagrilintide at 2.4 mg and semaglutide at 2.4 mg, administered as a once-weekly subcutaneous injection. The scientific rationale behind this combination is straightforward — GLP-1 receptor agonism and amylin receptor agonism regulate appetite and satiety through overlapping but distinct neurological pathways. Combining them produces additive effects that neither compound achieves alone.

Semaglutide is the GLP-1 receptor agonist component that researchers already know well from the STEP trial program. It reduces appetite through hypothalamic signaling, slows gastric emptying to extend post-meal satiety, and improves glycemic control through glucose-dependent insulin secretion. Semaglutide 2.4 mg alone produces approximately 15-17% mean body weight reduction over 68 weeks based on the STEP 1 trial data published in the New England Journal of Medicine.

Cagrilintide is the novel component. It is a long-acting analogue of amylin, a 37-amino acid peptide hormone co-secreted with insulin from pancreatic beta cells. Amylin acts on receptors in the area postrema and hypothalamus to reduce food intake, slow gastric emptying through a different mechanism than GLP-1, and suppress post-meal glucagon secretion. Pramlintide (Symlin) was the first FDA-approved amylin analogue, but its short half-life required dosing with every meal. Cagrilintide was engineered with fatty acid acylation to extend its half-life, enabling once-weekly administration.

The combination works because GLP-1 and amylin activate different neuronal populations. GLP-1 receptors are concentrated in the hypothalamic arcuate nucleus and paraventricular nucleus, while amylin receptors are densely expressed in the area postrema and nucleus of the solitary tract. Research published in the Journal of Medicinal Chemistry by Kruse et al. demonstrated that cagrilintide’s binding profile produces sustained amylin receptor activation that complements rather than duplicates semaglutide’s GLP-1 effects. This dual-pathway approach theoretically overcomes the satiety plateau that single-pathway agents encounter.

What Does the CagriSema Clinical Trial Data Show?

CagriSema has been evaluated in two major clinical programs: REDEFINE (for obesity and overweight) and REIMAGINE (for type 2 diabetes). Together, these programs represent one of the most comprehensive peptide clinical datasets in metabolic research.

REDEFINE 1 was the pivotal Phase 3a trial for weight management in adults without diabetes. It enrolled participants with a BMI of 30 or higher, or 27 or higher with at least one obesity-related complication, and randomized them to CagriSema 2.4/2.4 mg, semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, or placebo over 68 weeks. The results demonstrated approximately 22.7% mean body weight reduction with CagriSema, compared to roughly 16% with semaglutide alone and 8% with cagrilintide alone. While the combination fell slightly short of Novo Nordisk’s ambitious 25% target, it clearly demonstrated additive efficacy beyond either monotherapy.

REDEFINE 2 evaluated CagriSema specifically in adults with overweight or obesity and type 2 diabetes. Published in the New England Journal of Medicine, this trial randomized 1,507 participants across 12 countries to CagriSema 2.4/2.4 mg or placebo for 68 weeks. CagriSema produced 15.7% mean weight loss compared to 3.1% with placebo. Importantly, 89.7% of CagriSema participants achieved at least 5% weight loss, compared to 30.3% on placebo. The HbA1c reduction was also substantial — demonstrating dual metabolic benefits.

REDEFINE 4 was the open-label head-to-head comparison that generated significant attention. This 84-week trial compared CagriSema directly against tirzepatide 15 mg in 800 adults with obesity. CagriSema achieved 23% mean weight loss after 84 weeks. However, the trial did not meet its primary endpoint of demonstrating non-inferiority to tirzepatide 15 mg — meaning tirzepatide produced numerically greater weight loss in this direct comparison. This result was a pivotal moment for the field, establishing that tirzepatide’s GIP/GLP-1 dual agonism may produce greater weight reduction than amylin/GLP-1 combination at the doses studied.

REIMAGINE 2 focused on type 2 diabetes specifically. It enrolled 2,728 adults with T2D inadequately controlled on metformin. CagriSema at the 2.4/2.4 mg dose produced a 1.91 percentage point HbA1c reduction and 14.2% weight loss at 68 weeks, compared to 10.2% with semaglutide alone. No weight loss plateau was observed at the end of the treatment period — suggesting continued efficacy beyond 68 weeks. In this trial, 43% of participants on CagriSema achieved at least 15% weight loss, and 24% achieved at least 20%.

How Does CagriSema Compare to Other Metabolic Research Peptides?

The metabolic peptide landscape in 2026 includes several multi-pathway approaches, each targeting different receptor combinations. Understanding where CagriSema fits requires comparing it to the other leading compounds researchers are studying. For a broader overview of the weight loss peptide category, see our guide to the best peptides for weight loss.

The comparison reveals an important pattern: CagriSema’s additive weight loss over semaglutide alone (~6-7 percentage points) confirms the value of dual-pathway approaches. However, retatrutide’s triple-agonist mechanism (GIP + GLP-1 + glucagon) produced comparable or greater weight loss in a shorter Phase 2 timeframe — and its Phase 3 TRIUMPH program is evaluating 96-week endpoints that could show even larger effects. For a detailed analysis of how retatrutide’s triple-receptor approach differs from CagriSema’s dual-pathway strategy, see our semaglutide vs retatrutide vs tirzepatide comparison.

The REDEFINE 4 head-to-head result against tirzepatide is particularly informative. Despite targeting two pathways, CagriSema did not achieve non-inferiority to tirzepatide’s GIP/GLP-1 dual agonism at the doses tested. This suggests that the specific receptor combinations matter as much as the number of pathways engaged, and that GIP receptor activation may contribute more to weight loss than amylin receptor activation at currently studied doses.

What Is the Side Effect Profile of CagriSema?

The safety data from CagriSema’s clinical program is consistent with what researchers expect from GLP-1 and amylin-based compounds. Gastrointestinal adverse events are the most commonly reported — nausea, vomiting, diarrhea, and constipation occurred at rates similar to or slightly higher than semaglutide monotherapy. Across the REDEFINE and REIMAGINE programs, these GI effects were described as mild to moderate in intensity and typically diminished over the dose-titration period.

The addition of cagrilintide does not appear to introduce a qualitatively different side effect profile compared to semaglutide alone. The amylin pathway also affects gastric emptying, which likely contributes to some additive GI effects during initial dosing. However, the titration schedule — gradually increasing to the full 2.4/2.4 mg dose — was designed to mitigate this. Researchers studying peptide side effects more broadly will note that the CagriSema tolerability profile aligns with the class-wide pattern seen across GLP-1-based compounds.

A notable observation from REDEFINE 1: the dose-titration schedule may have been too aggressive for some participants. Approximately half of participants reached the highest dose, which may explain why the 25% weight loss target was not met across the full population. Novo Nordisk has indicated that longer titration periods could improve both tolerability and efficacy outcomes — a hypothesis being tested in ongoing studies.

Understanding the Amylin Pathway: Why Cagrilintide Matters

The cagrilintide component of CagriSema deserves special attention because amylin biology is less widely understood than GLP-1 signaling among peptide researchers. Amylin is a 37-amino acid peptide co-secreted with insulin from pancreatic beta cells in response to nutrient intake. It acts on calcitonin receptor/RAMP complexes (CTR/RAMP1, CTR/RAMP3) to produce several effects relevant to metabolic research.

First, amylin reduces food intake through direct action on area postrema neurons — a circumventricular organ that lacks a complete blood-brain barrier, allowing circulating peptides to access central neurons directly. Second, amylin slows gastric emptying through vagal efferent pathways that are partially distinct from GLP-1-mediated gastric slowing. Third, amylin suppresses post-meal glucagon secretion, reducing hepatic glucose output. These effects are complementary to GLP-1’s actions rather than redundant.

Cagrilintide itself was engineered to overcome the pharmacokinetic limitations of native amylin and pramlintide. The Journal of Medicinal Chemistry publication by Kruse et al. (2021) detailed the development process: fatty acid acylation at position Lys-1 enabled albumin binding, extending the half-life from minutes (pramlintide) to approximately 160 hours — sufficient for once-weekly dosing. In Phase 2 dose-finding studies, cagrilintide 2.4 mg alone produced approximately 10.8% weight loss at 26 weeks, establishing it as a meaningful monotherapy before combination with semaglutide.

PSPeptides offers cagrilintide as a standalone research compound alongside the CagriSema combination, allowing researchers to study the amylin pathway independently or in combination protocols.

CagriSema Reconstitution and Research Protocols

For researchers working with lyophilized CagriSema, proper reconstitution and handling are critical to maintaining peptide integrity. CagriSema is supplied as a lyophilized powder and should be reconstituted with bacteriostatic water using standard aseptic technique.

The reconstitution process follows the same principles outlined in our complete guide to peptide reconstitution. Direct the bacteriostatic water stream against the vial wall rather than directly onto the lyophilized cake. Allow the powder to dissolve gradually with gentle swirling — never shake the vial, as mechanical stress can denature peptide bonds. For dosing calculations, our peptide dosage calculator guide provides step-by-step instructions for converting between milligrams and volume measurements.

Storage considerations are important for maintaining CagriSema stability. Unreconstituted vials should be stored at 2-8°C (standard refrigerator temperature) protected from light. Once reconstituted with bacteriostatic water, the solution should be refrigerated and used within 28-30 days. Do not freeze reconstituted peptide solutions. For comprehensive storage protocols, see our peptide storage guide.

Researchers designing protocols should be aware that the clinical trial dose of CagriSema (2.4 mg cagrilintide + 2.4 mg semaglutide) was reached through a multi-week titration schedule starting at lower doses. The titration was implemented to minimize gastrointestinal adverse events during the initial weeks of administration.

What Is the Regulatory Status of CagriSema in 2026?

Novo Nordisk submitted a New Drug Application (NDA) to the FDA in December 2025 for CagriSema as a weight management treatment. The application was based primarily on REDEFINE 1 data. If approved, CagriSema could become available as a prescription medication as early as late 2026, though FDA review timelines are not guaranteed.

Several important regulatory developments are worth tracking. The REDEFINE 3 trial — a cardiovascular outcomes trial enrolling 7,000 adults — remains ongoing and could provide the cardiovascular benefit data that would strengthen CagriSema’s competitive position against tirzepatide (which already has SELECT-like cardiovascular data through semaglutide’s approved label). The REDEFINE 4 non-inferiority result against tirzepatide, while not what Novo Nordisk hoped for, does not prevent FDA approval — it simply means CagriSema’s label may position it relative to semaglutide rather than claiming equivalence to tirzepatide.

For researchers following the broader regulatory landscape, our FDA peptide reclassification guide covers the April 2026 changes that removed several peptides from the Category 2 restricted list and the July 2026 advisory committee meetings reviewing additional compounds.

Why CagriSema Research Is Accelerating in 2026

The convergence of several factors has made CagriSema one of the most actively studied peptide combinations in metabolic research. The REDEFINE program demonstrated that amylin/GLP-1 combination produces genuinely additive weight loss — resolving a longstanding question about whether targeting additional satiety pathways could overcome the efficacy ceiling of GLP-1 monotherapy. The fact that approximately one-quarter of CagriSema participants in REIMAGINE 2 achieved 20% or greater weight loss is a threshold that was essentially unachievable with single-pathway approaches.

The comparison to retatrutide is particularly informative for researchers deciding which compounds to study. CagriSema targets satiety and appetite through amylin + GLP-1, while retatrutide targets metabolic rate and appetite through GIP + GLP-1 + glucagon. The glucagon component in retatrutide drives thermogenesis and hepatic fat oxidation — metabolic effects that amylin does not produce. This mechanistic difference may explain why retatrutide’s Phase 2 data showed numerically higher weight loss despite a shorter treatment duration. For a broader understanding of how different receptor pathways shape metabolic peptide research, see our complete guide to peptides.

The emerging field of combination peptide research extends beyond weight loss. CagriSema’s glycemic data — particularly the HbA1c reductions in the REIMAGINE program — suggest that amylin/GLP-1 combinations may offer advantages for metabolic health markers beyond what weight loss alone would predict. Researchers studying AOD-9604 and other metabolic peptides are increasingly comparing outcomes across receptor-class boundaries rather than within a single pathway.

Further Reading

For additional peer-reviewed research, see: CagriSema REDEFINE 2 trial published in the New England Journal of Medicine.

Understanding cagrisema is essential for researchers navigating this rapidly evolving field in 2026.

Frequently Asked Questions

What is CagriSema and what makes it different from semaglutide alone?

CagriSema is a combination of cagrilintide (a long-acting amylin analogue) and semaglutide (a GLP-1 receptor agonist) in a single weekly injection. It differs from semaglutide alone by targeting two distinct satiety pathways — amylin receptors in the area postrema and GLP-1 receptors in the hypothalamus — which produces approximately 6-7 percentage points more weight loss than semaglutide monotherapy in clinical trials.

How much weight loss does CagriSema produce in clinical trials?

In the REDEFINE 1 trial, CagriSema produced approximately 22.7% mean body weight reduction at 68 weeks. The REDEFINE 4 trial showed 23% weight loss at 84 weeks. In participants with type 2 diabetes (REIMAGINE 2), the result was 14.2% weight loss at 68 weeks — higher than the 10.2% achieved with semaglutide alone in the same trial.

Is CagriSema FDA approved?

As of mid-2026, CagriSema is not FDA approved. Novo Nordisk submitted a New Drug Application in December 2025, and FDA review is expected during 2026. If approved, it would be marketed as a prescription weight management medication. Research-grade CagriSema is available from suppliers like PSPeptides for laboratory use.

How does CagriSema compare to retatrutide?

CagriSema combines amylin + GLP-1 pathways (two satiety mechanisms), while retatrutide combines GIP + GLP-1 + glucagon pathways (appetite suppression plus thermogenesis). Retatrutide’s Phase 2 data showed approximately 24.2% weight loss in 48 weeks — numerically higher than CagriSema’s results over a shorter timeframe. The key difference is that retatrutide’s glucagon component drives metabolic rate increases that amylin does not provide.

All PSPeptides products are sold exclusively for research and laboratory use.